🇨🇭 Swiss Precision & Compliance

AI-Powered Innovation

AI-powered clinical trial innovation

By combining advanced analytics, machine learning, and structured data systems, Wemedoo enables smarter decision-making, reduces operational complexity, and helps research teams design, execute, and optimize clinical trials with greater confidence, speed, and precision.

Request a Demo Contact Us
21 CFR Part 11 ICH-GCP GDPR GxP-aligned

AI Foundations

Built on science, designed for impact

At Wemedoo, our Artificial Intelligence (AI) capabilities are grounded in peer-reviewed research and real-world clinical data. Our approach is built on large-scale evidence synthesis, including a comprehensive review of nearly 18,000 scientific records that established a standardized methodology for understanding clinical trial failure.

By integrating advanced analytics directly into clinical workflows, Wemedoo enables sponsors, CROs, and research organizations to design smarter studies, reduce uncertainty, and accelerate outcomes with confidence.

Risk Assessment

AI-supported clinical trial risk assessment

We provide advanced, explainable AI models that assess the risk of clinical trial failure early in the design phase.

Built on a comprehensive, peer-reviewed evidence base, our methodology synthesizes thousands of scientific publications and applies machine learning trained on over 83,000 interventional trials.

Early identification of high-risk study designs

Study-specific risk profiles highlighting modifiable factors

Optimization of trial protocols before execution

Focused allocation of resources where they matter most

Literature Review

AI-accelerated literature review

Wemedoo automates one of the most time-consuming steps in clinical research: identifying and evaluating relevant scientific evidence. It solves this challenge by transforming a manual, fragmented process into a unified, AI-driven workflow:

Select therapeutic area Identify relevant studies Extract structured data Validate and apply insights

Using a combination of large language models, natural language processing, and ontology-based tagging, our system rapidly screens and structures biomedical literature with high precision.

Fast identification of relevant clinical studies and publications

Automated classification and data extraction

Ontology-based tagging for structured analysis

Scalable literature screening across millions of publications

Protocol Authoring

Intelligent protocol authoring

Wemedoo combines advanced large language models with structured, regulatory-compliant authoring to transform how protocols are developed.

With our Protocol Master, we go beyond standard AI text generation by embedding intelligence into a fully auditable, collaborative system aligned with CDISC standards.

AI-assisted drafting with built-in validation and control

Structured authoring aligned with industry standards (USDM, CDISC)

Full audit trails, versioning, and traceability

Seamless integration with downstream systems (EDC, CTMS, data platforms)

Data Modeling

Biomedical concepts and structured data modeling

Wemedoo supports advanced modeling of biomedical concepts to connect endpoints, data collection, and regulatory standards.

By linking protocol definitions to CDISC-compliant datasets, our system enables consistent, reusable, and machine-readable data structures across the clinical trial lifecycle.

Clear mapping from protocol concepts to CRFs and datasets

Alignment with National Cancer Institute's Thesaurus (NCIT) terminology and CDISC standards

Improved data consistency and submission readiness

Foundation for metadata-driven automation

Drug Development

AI-supported drug development

By combining knowledge graphs, large-scale literature mining, and curated datasets, we create a connected view of the biomedical and clinical research ecosystem, supporting key areas such as target and indication selection, biomarker discovery, endpoint definition, and trial feasibility with patient stratification.

Genes, pathways, drugs, diseases, endpoints, and trials are connected in a single semantic graph

AI identifies relationships, patterns, and emerging signals across these data layers

Insights are translated into testable, evidence-backed hypotheses

Get Started

Unlock AI-powered clinical research

Explore the full potential of Wemedoo and see how our AI capabilities power a smarter approach to clinical trials

Explore Wemedoo

Frequently asked questions (FAQ)

How does Wemedoo use AI in clinical trials?

Wemedoo applies AI across the clinical trial lifecycle, including risk assessment, literature review, protocol authoring, and drug development. These capabilities are built on peer-reviewed research and structured data models to provide reliable, explainable insights that support decision-making.

Is Wemedoo's AI explainable and transparent?

Yes. Our AI models are designed to provide clear, study-specific insights, including identification of risk drivers and evidence trails. Transparency and interpretability are key to ensuring trust and regulatory acceptance.

How does AI improve clinical trial success rates?

AI helps identify risks early, optimize protocol design, and improve endpoint selection. By addressing critical factors before trials begin, organizations can reduce delays, lower costs, and increase the likelihood of successful outcomes.

Can Wemedoo AI replace human expertise?

No. Wemedoo AI is designed to support clinical teams, not replace them. It enhances human decision-making by providing data-driven insights while keeping experts in control of final decisions.

How does Wemedoo ensure data quality and compliance?

Wemedoo integrates AI within a structured, compliant framework aligned with CDISC standards, GCP principles, and regulatory requirements. Full audit trails, traceability, and governance are embedded across all processes.

What makes Wemedoo's AI approach different?

Our approach combines peer-reviewed science, large-scale clinical data, explainable machine learning, and structured data standards in one connected system. This ensures that AI outputs are not only accurate but also actionable and regulatory-ready.